Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus. After all, the pleasing sounds of nature can still be heard outside our window and a cool breeze is wafting by. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Our choice today is salted caramel mocha, which provides a faint whiff of the Jersey shore, such as it is. Meanwhile, here are a few tidbits to digest. We hope you have a smashing day and, as always, stay in touch. …

Three moderate House Democrats are making good on their threat to oppose Speaker Nancy Pelosi’s aggressive Medicare drug price-negotiation plan, leaving its fate uncertain, STAT explains. Reps. Scott Peters (Calif.), Kurt Schrader (Ore.), and Kathleen Rice (N.Y.) have publicly stated their intentions to vote down Pelosi’s drug-pricing plan as part of the House Energy & Commerce Committee’s markup on a sprawling safety-net package Democrats are advancing this week.


Meanwhile, an influential Senate Democrat is pushing back against his party’s efforts to cut $600 billion out of the pharmaceutical industry as part of a massive yet-to-be-unveiled spending package, STAT reports. “I’ve made clear that the idea of $600 billion out of the hide of the pharmaceutical industry, that dog doesn’t hunt. But they have to be willing to be part of the solution,” said Sen. Tom Carper (D-Del.), regarding the pharmaceutical industry. “It is not gonna be $600 billion.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.